Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

WinHealth Pharma Licenses World’s First Oral Arsenic Trioxide Arsenol for Mainland China APL Treatment

Fineline Cube Apr 14, 2026
Company Deals

Thermo Fisher’s PPD Secures 270M-Patient HealthVerity Dataset for AI-Driven Clinical Trial Optimization

Fineline Cube Apr 14, 2026
Company Deals

China Resources and Roche Partner on Trastuzumab Emtansine Commercialization to Expand Breast Cancer ADC Access

Fineline Cube Apr 14, 2026
Company Deals

CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China’s NHL Market

Fineline Cube Apr 14, 2026
Company Deals

Erasca Exercises Option to Secure Global Rights to Pan-RAS Molecular Glue ERAS-0015 from Joyo Pharmatech

Fineline Cube Apr 14, 2026
Policy / Regulatory

FDA Issues Draft Guidance for Genome Editing Therapy Safety Assessment Using Next-Generation Sequencing

Fineline Cube Apr 15, 2026
Company Drug

Laekna Therapeutics Reports Breakthrough Phase III Results for LAE002 AKT Inhibitor in HR+/HER2- Breast Cancer

Fineline Cube Apr 15, 2026
Company Drug

Xuanzhu Biopharma Receives NMPA Approval for Phase III Trial of Anaprazole-Based Quadruple Therapy Against H. pylori

Fineline Cube Apr 15, 2026
Company Deals

PureID Medical Technology Secures RMB 100M Series B Funding

Fineline Cube Oct 18, 2022

PureID Medical Technology Co., Ltd, a medical device compliance service provider based in Guangzhou, has...

Company Drug

Sinocelltech’s COVID-19 Vaccines SCTV01C and SCTV01E Show Promising Phase III Results

Fineline Cube Oct 18, 2022

China-based Sinocelltech Group Ltd (SHA: 688520) has announced the preliminary interim analysis results of a...

Company Drug

Jemincare’s Sonidegib Receives First Prescriptions in China for Basal Cell Carcinoma

Fineline Cube Oct 18, 2022

China-based Jiangxi Jemincare Group has announced the first prescriptions in China for its sonidegib, a...

Company Deals

Salus Biomed Raises Over RMB 100M in Pre-Series A Financing

Fineline Cube Oct 18, 2022

Salus Biomed, a sequencing and spatial omics platform provider based in Guangdong, has reportedly raised...

Company Drug

Haisco Pharma’s Ciprofol Injection Gains NMPA Approval for Gynecology Use

Fineline Cube Oct 18, 2022

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced receiving another marketing approval from...

Company Drug

ScienCare Pharma’s Naltrexone Implant Prioritized for Review by CDE

Fineline Cube Oct 18, 2022

The Center for Drug Evaluation (CDE) website indicates that the market filing by China-based Shenzhen...

Company Drug

Grand Pharma’s TLX591-CDx Approved for Prostate Cancer Diagnosis in China

Fineline Cube Oct 18, 2022

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its Investigational New Drug (IND)...

Company Deals

Kunshi Biotechnology Raises Angel Funding for Engineered Macrophage Platform

Fineline Cube Oct 17, 2022

China-based Kunshi Biotechnology (Shenzhen) Co., Ltd, a company specializing in gene editing, biomaterials, and synthetic...

Company Drug

Akeso Biopharma’s Cadonilimab Recommended as First-Line Treatment for Cervical Cancer

Fineline Cube Oct 17, 2022

China-based biotech Akeso Biopharma (HKG: 9926) has revealed that its cadonilimab (AK104) has been included...

Company Drug

Fosun Kite’s Yescarta Gains Priority Review Status for r/r LBCL

Fineline Cube Oct 17, 2022

China-based Fosun Kite Biotechnology Co., Ltd, a joint venture (JV) between Shanghai Fosun Pharmaceutical (Group)...

Company Drug

Genor Biopharma Initiates First Patient Dosing for GB263T in China

Fineline Cube Oct 17, 2022

China’s Genor Biopharma Co., Ltd (HKG: 6998) has announced the first patient dosing in a...

Company Drug

Akeso Biopharma Gains NMPA Approval for AK112 and AK119 Clinical Study

Fineline Cube Oct 17, 2022

China-based Akeso Biopharma (HKG: 9926) has announced receiving approval from the National Medical Products Administration...

Company Drug

Innovent Biologics Publishes Mazdutide Phase Ib Study Results for Obesity

Fineline Cube Oct 17, 2022

China-based Innovent Biologics, Inc. (HKG: 1801) has announced that the results of the higher-dose cohorts...

Company Deals

Sihuan Pharma to Acquire Additional Stake in Heilongjiang Duoduo Pharma

Fineline Cube Oct 17, 2022

China-based Sihuan Pharmaceutical Holdings Group Ltd’s subsidiary, Beijing Centergate Technologies (Holding) Co., Ltd (SHE: 000931),...

Policy / Regulatory

NHSA Completes Expert Review for NRDL Price Negotiation Process

Fineline Cube Oct 17, 2022

The National Healthcare Security Administration (NHSA) has released a notification indicating that the expert review...

Company Drug

BeiGene’s Brukinsa Receives Positive CHMP Opinion for CLL Approval

Fineline Cube Oct 17, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced receiving a positive opinion...

Company Drug

Kira Pharmaceuticals Gains NMPA Approval for Phase II Study of KP104 in PNH

Fineline Cube Oct 17, 2022

Sino-US biotech Kira Pharmaceuticals has announced receiving approval from the National Medical Products Administration (NMPA)...

Company Drug

RemeGen’s Telitacicept Gains EU, China Approvals for Global Phase III Study

Fineline Cube Oct 17, 2022

China-based pharma firm RemeGen (HKG: 9995) has announced receiving approvals from authorities in the European...

Company Drug

Zelgen’s Jacktinib Shows Strong Efficacy in Phase III Myelofibrosis Study

Fineline Cube Oct 17, 2022

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has published major data from a Phase III...

Company Deals

Ningbo Menovo to Sell Zhejiang Liaoyuan Pharma Stake to Jemincare for RMB 512.58M

Fineline Cube Oct 17, 2022

China-based Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538) has announced plans to transfer all of...

Posts pagination

1 … 599 600 601 … 651

Recent updates

  • Laekna Therapeutics Reports Breakthrough Phase III Results for LAE002 AKT Inhibitor in HR+/HER2- Breast Cancer
  • Johnson & Johnson Reports Strong Q1 2026 Sales Growth Despite Net Earnings Decline; Raises Full-Year Guidance
  • Xuanzhu Biopharma Receives NMPA Approval for Phase III Trial of Anaprazole-Based Quadruple Therapy Against H. pylori
  • Shanghai Henlius Biotech Launches Phase I Trial for HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer
  • Beijing Sinotau’s Prostate Cancer Diagnostic Agent XTR020 Receives NMPA Review Acceptance
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Laekna Therapeutics Reports Breakthrough Phase III Results for LAE002 AKT Inhibitor in HR+/HER2- Breast Cancer

Company

Johnson & Johnson Reports Strong Q1 2026 Sales Growth Despite Net Earnings Decline; Raises Full-Year Guidance

Company Drug

Xuanzhu Biopharma Receives NMPA Approval for Phase III Trial of Anaprazole-Based Quadruple Therapy Against H. pylori

Company Drug

Shanghai Henlius Biotech Launches Phase I Trial for HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.